A formulation that works in a vial in the lab is only the start. Translation means making it reproducibly, at scale, under GMP, with proven quality, stability and safety — so regulators and patients can rely on every batch.
- Quality framework
- QbD, ICH Q8–Q11
- Scale-up methods
- Microfluidic, T-mixer, extrusion
- Typical bottleneck
- Reproducibility & CMC
Many nanomedicines succeed in preclinical studies but stall before or during clinical development. The reasons are often not biological but chemistry, manufacturing and controls (CMC): inconsistent particle size between batches, poor stability, impure raw materials or processes that cannot be scaled.
Quality by Design (QbD) addresses this by defining a quality target product profile, identifying the critical quality attributes (CQAs) — size, PDI, encapsulation, potency, purity — and linking them to critical process parameters (CPPs) such as mixing rate, flow-rate ratio, temperature and buffer composition.
The path from bench to clinic then runs through process development, analytical method validation, stability studies, GMP manufacturing, preclinical toxicology and a regulatory submission such as an IND or IMPD.
Pillars of successful translation
Scalable process
Methods such as microfluidic or impingement-jet mixing give the same particles at 1 mL and at 100 L.
Analytical control
Validated assays for size, charge, encapsulation, lipid or polymer content, identity and potency.
Stability
Real-time and accelerated studies, often with lyophilisation or frozen storage, to set shelf life.
Regulatory strategy
Early dialogue with agencies on CMC, non-clinical safety and clinical design.
How it works
- 1
Lock the formulation
Fix composition, ratios and excipients using design-of-experiments data.
- 2
Develop the process
Define mixing, purification (tangential flow filtration), sterile filtration and fill–finish steps.
- 3
Scale up and transfer
Demonstrate comparability across scales and transfer to a GMP facility.
- 4
Release and file
Manufacture GMP batches, test against specifications and submit the regulatory dossier.
Critical quality attributes
| Attribute | Typical method | Why it matters |
|---|---|---|
| Particle size and PDI | DLS | Controls biodistribution and stability |
| Encapsulation efficiency | Fluorescence dye assay, HPLC | Free payload affects safety and potency |
| Lipid or polymer content | HPLC-CAD/ELSD | Confirms composition and identity |
| Payload integrity | Capillary electrophoresis, LC-MS | Degraded cargo loses activity |
| Potency | Cell-based expression or activity assay | Links quality to biological effect |
| Sterility and endotoxin | Compendial tests | Mandatory for injectables |
Manufacturing methods compared
| Method | Scale | Strength | Limitation |
|---|---|---|---|
| Thin-film hydration + extrusion | Lab to pilot | Simple, widely used for liposomes | Batch process, hard to scale |
| Microfluidic mixing | µL to L | Excellent size control and reproducibility | Parallelisation needed for large volumes |
| T-junction / impingement jet | L to 100s of L | Continuous, industrial scale | Requires process engineering |
| Nanoprecipitation | Lab to pilot | Good for polymeric nanoparticles | Solvent removal and control |
| Spray drying / lyophilisation | Pilot to commercial | Dry, stable products | Stress on particles and payload |
Strengths
- Proven pathway. Approved liposomes and LNP medicines provide regulatory precedent.
- Continuous manufacturing. Flow processes improve consistency and reduce scale-up risk.
- Platform approach. One validated process can serve many payloads.
- Better analytics. Modern tools characterise complex nanomedicines in detail.
Challenges
- Batch variability. Small process changes alter size, loading and performance.
- Raw-material quality. Specialised lipids and polymers need GMP supply and full characterisation.
- Cold chain. Many products need frozen or refrigerated storage and distribution.
- Cost and time. GMP facilities, validation and toxicology are expensive and slow.
Where it is used
Clinical supply
GMP batches for phase I–III trials.
Technology transfer
Moving processes between partners and contract manufacturers.
Lifecycle management
Reformulating approved drugs for better delivery or new routes.
Pandemic response
Rapid scale-up of LNP manufacturing for billions of vaccine doses.
What comes next
Manufacturing is becoming more continuous, digital and flexible, shortening the road from discovery to patients.
Process analytical technology
In-line size and concentration monitoring for real-time release.
Modular and distributed GMP
Small, mobile facilities producing personalised or regional medicines.
Thermostable formulations
Lyophilised nanomedicines that remove the need for deep-cold storage.
Digital twins
Process models that predict product quality and speed up scale-up.
Translation succeeds when quality is designed in from the start — a reproducible, scalable, well-characterised process is what turns a promising nanocarrier into an approved medicine.